All Stories

  1. Design, Synthesis, and Characterization of Novel, Subtype-Selective Fluorescent Antagonists Targeting the Nociceptin/Orphanin FQ Opioid Peptide Receptor
  2. Shaping Future Medicinal Chemists: Perspectives from European Schools of Pharmacy within the GP2A Network
  3. Assessment of the potential of novel and classical opioids to induce respiratory depression in mice
  4. Design, Synthesis, and Application of Fluorescent Ligands Targeting the Intracellular Allosteric Binding Site of the CXC Chemokine Receptor 2
  5. M 1 muscarinic receptor activation reduces the molecular pathology and slows the progression of prion-mediated neurodegenerative disease
  6. Development of fluorescent peptide G protein‐coupled receptor activation biosensors for NanoBRET characterization of intracellular allosteric modulators
  7. Optimization of Peptide Linker-Based Fluorescent Ligands for the Histamine H1 Receptor
  8. Development of fluorescent peptide G Protein Coupled Receptor activation biosensors for NanoBRET characterisation of intracellular allosteric modulators
  9. 27th Annual GP2A Medicinal Chemistry Conference
  10. Structure–Kinetic Profiling of Haloperidol Analogues at the Human Dopamine D2 Receptor
  11. A Thieno[2,3-d]pyrimidine Scaffold Is a Novel Negative Allosteric Modulator of the Dopamine D2 Receptor
  12. Novel selective β1-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease
  13. New strategy to improve the current antipsychotics for treating symptoms of schizophrenia
  14. GPCRs through the keyhole: the role of protein flexibility in ligand binding to β-adrenoceptors
  15. Novel Fused Arylpyrimidinone Based Allosteric Modulators of the M1 Muscarinic Acetylcholine Receptor
  16. Potent dual inhibitors of Plasmodium falciparum M1 and M17 aminopeptidases through optimization of S1 pocket interactions
  17. 4-Phenylpyridin-2-one Derivatives: A Novel Class of Positive Allosteric Modulator of the M1 Muscarinic Acetylcholine Receptor
  18. Discovery of a Novel Class of Negative Allosteric Modulator of the Dopamine D2 Receptor Through Fragmentation of a Bitopic Ligand
  19. Structure–Activity Study of N-((trans)-4-(2-(7-Cyano-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)-1H-indole-2-carboxamide (SB269652), a Bitopic Ligand That Acts as a Negative Allosteric Modulator of the Dopamine D2 Receptor
  20. Screening the Medicines for Malaria Venture "Malaria Box" against the Plasmodium falciparum Aminopeptidases, M1, M17 and M18
  21. Biased allosteric modulation at the CaS receptor engendered by structurally diverse calcimimetics
  22. Two-Pronged Attack: Dual Inhibition of Plasmodium falciparum M1 and M17 Metalloaminopeptidases by a Novel Series of Hydroxamic Acid-Based Inhibitors
  23. Mechanistic Insights into Allosteric Structure-Function Relationships at the M1Muscarinic Acetylcholine Receptor
  24. Triphenylphosphonium Anhydride Trifluoromethanesulfonate
  25. Molecular Determinants of Allosteric Modulation at the M1Muscarinic Acetylcholine Receptor
  26. Synthesis and Pharmacological Profiling of Analogues of Benzyl Quinolone Carboxylic Acid (BQCA) as Allosteric Modulators of the M1 Muscarinic Receptor
  27. Synthesis and in Vitro and in Vivo Characterization of Highly β1-Selective β-Adrenoceptor Partial Agonists
  28. 4,5-Dihydro-1-[(1S)-1-(hydroxymethyl)-2,2-dimethylpropyl]-3-(2,4,6-trimethylphenyl)-1H-imidazolium Hexafluorophosphate
  29. Synthesis and Characterization of High-Affinity 4,4-Difluoro-4-bora-3a,4a-diaza-s-indacene-Labeled Fluorescent Ligands for Human β-Adrenoceptors
  30. Triphenylphosphonium Anhydride Trifluoromethanesulfonate